Article Details
Retrieved on: 2025-02-04 14:14:23
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article details Supernus Pharmaceuticals' ONAPGO, a subcutaneous apomorphine device for advanced Parkinson’s disease, emphasizing its advantages over levodopa. Tags highlight its relation to CNS treatments, dopamine agonists, and relevant stakeholders, excluding Zeiss.
Article found on: www.taiwannews.com.tw
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here